DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Graft vs Host Disease
Hodgkin's Disease
Multiple Myeloma
Non Hodgkin's Lymphoma

First Posted Date: 1999-11-04

Last Posted Date: 2018-07-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT00001830

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Phase 1

Completed

Conditions: Breast Cancer
Prostatic Neoplasm
Lymphoma
Neoplasm

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00001444

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Phase I Study of Intrathecal Mafosfamide

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Meningeal Neoplasm

First Posted Date: 1999-11-04

Last Posted Date: 2013-08-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT00001251

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

Phase 1

Completed

Conditions: Colorectal Neoplasm
Liver Neoplasm
Neoplasm Metastasis

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00001576

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma
Neoplasm Metastasis

Interventions: Drug: IL-2
Procedure: Apheresis
Biological: Abl cells
Drug: Montanide ISA-51
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: GCSF (Growth colony stimulating factor)

First Posted Date: 1999-11-04

Last Posted Date: 2012-12-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 170

Registration Number: NCT00001832

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

Completed

Conditions: B-Cell Lymphoma
ATL
Myeloma
T-cell Lymphoma

First Posted Date: 1999-11-04

Last Posted Date: 2023-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 902

Registration Number: NCT00001582

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Studies of States With Resistance to Vitamin D and Parathyroid Hormone

Completed

Conditions: Rickets
Hypocalcemia
Pseudohypoparathyroidism
Pseudopseudohpoparathyroidism
Osteomalacia

First Posted Date: 1999-11-04

Last Posted Date: 2023-01-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 70

Registration Number: NCT00001242

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Biological: incomplete Freund's adjuvant
Biological: von Hippel-Lindau peptide vaccine

First Posted Date: 1999-11-04

Last Posted Date: 2014-07-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT00001703

Locations: 🇺🇸
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

Studies With 1,25-Dihydroxycholecalciferol

Phase 2

Terminated

Conditions: Hypocalcemia
Rickets

Interventions: Drug: 1,25-Dihydroxycholecalciferol

First Posted Date: 1999-11-04

Last Posted Date: 2013-11-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 6

Registration Number: NCT00001151

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease

Completed

Conditions: Cancer
HIV

First Posted Date: 1999-11-04

Last Posted Date: 2019-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2145

Registration Number: NCT00001295

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy